ArticleJournal of Crohn's & colitis2018

Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn's Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN/ADHERE Trials.

Remo Panaccione et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.